JAK2 and essential thrombocythemia: Other common first‐line therapies were anagrelide (10%) and interferon (9%) in patients with ET, cytoreductive therapy (6%) and clopidogrel (6%) in patients with PV, and JAK2 inhibitors (15%) in patients with MF.